Anavex Life Sciences (AVXL) Other financing activities (2012 - 2025)
Anavex Life Sciences (AVXL) reported Other financing activities of $1.3 million for Q3 2025, up 1320.22% on a YoY basis from $89000.0 in Q3 2024, and up 962.18% sequentially from $119000.0 in Q2 2025.
Anavex Life Sciences (AVXL) Other financing activities (2012 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 8 years of Other financing activities data on file, last reported at $1.3 million in Q3 2025.
- For the quarter ending Q3 2025, Other financing activities rose 1320.22% year-over-year to $1.3 million; the trailing twelve-month figure through Sep 2025 stood at $2.9 million (up 325.9% YoY), and the FY2025 full-year result was $2.9 million, up 325.9% from the prior year.
- Other financing activities advanced to $1.3 million in Q3 2025, from $119000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $1.3 million in Q3 2025 to a low of -$401408.0 in Q3 2021.
- A 5-year average of $401238.9 and a median of $374724.0 in 2022 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities jumped 456942.11% in 2023 and slumped 89.75% in 2024, its largest moves.
- Tracing AVXL's Other financing activities over 5 years: stood at $146717.0 in 2021, then soared by 75.85% to $258000.0 in 2022, then slumped by 77.13% to $59000.0 in 2023, then soared by 1100.0% to $708000.0 in 2024, then soared by 78.53% to $1.3 million in 2025.
- Business Quant data shows AVXL's Other financing activities at $1.3 million in Q3 2025, $119000.0 in Q2 2025, and $852000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.26 Mn |
| Sep 30, 2025 | 1.26 Mn |
| Jun 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 119,000.00 |
| Mar 31, 2025 | 852,000.00 |
| Mar 31, 2025 | 852,000.00 |
| Dec 31, 2024 | 708,000.00 |
| Dec 31, 2024 | 708,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 444,000.00 |
| Jun 30, 2024 | 444,000.00 |
| Mar 31, 2024 | 99,000.00 |
| Mar 31, 2024 | 99,000.00 |
| Dec 31, 2023 | 59,000.00 |
| Dec 31, 2023 | 59,000.00 |
| Sep 30, 2023 | 868,000.00 |
| Sep 30, 2023 | 868,000.00 |
| Jun 30, 2023 | 469,000.00 |
| Jun 30, 2023 | 469,000.00 |